LIVMARLI Tablet formulation approved for patients with Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic ...

The Food and Drug Administration (FDA) has approved a tablet formulation of Livmarli ® (maralixibat).

On April 14, 2025, the FDA approved a tablet formulation of maralixibat (Livmarli; Mirum Pharmaceuticals) for patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis ...

(Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI ® (maralixibat) for the treatment of cholestatic pruritus in ...

Mirum announced the FDA approved a new tablet formulation of Livmarli for the treatment of cholestatic pruritus in patients with Alagille ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--$MIRM #alagillesyndrome--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration ...

Shares of Mirum Pharmaceuticals, Inc. (MIRM) were in the spotlight on Monday after the company announced that the U.S. Food ...

In the gastric environment the surface of the tablet transforms into a gel through ... This new tramadol once-daily (OAD) formulation was created with the aim of providing continuous drug delivery ...

India's go-to paracetamol tablet, gained popularity during Covid. Experts now warn of liver risks from overuse. Here's how ...

In a world increasingly focused on health and wellness, the quest for optimal nutrition and vitality has led to the rise of innovative supplements. Among these, H2Tab stands out as a groundbreaking ...